Lipocine Streamlines Its Infringement Lawsuit Against Clarus Therapeutics

Lipocine Streamlines Its Infringement

Lawsuit Against Clarus Therapeutics

SALT LAKE CITY, February 11, 2020 -- Lipocine Inc. (NASDAQ:

LPCN), a clinical-stage biopharmaceutical company, announced today that in an effort to streamline the issues and associated costs

for dispute in its infringement lawsuit against Clarus Therapeutics, Inc. ("Clarus") in the United States District Court

("Delaware") related to the infringement of six Lipocine U.S. Patents by Clarus's JATENZO product, Lipocine has

voluntarily dismissed its allegations of patent infringement for expired U.S. Patent Nos. 6,569,463 and 6,923,988. Lipocine

continues to vigorously defend its patent rights and maintains its allegations for patent infringement of four U.S. patents -

U.S. patent nos. 9,034,858; 9,205,057; 9,480,690; and 9,757,390 - by Clarus's JATENZO product, which has yet to

Lipocine Inc. is a clinical-stage biopharmaceutical company

focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development

pipeline includes TLANDO, LPCN 1144, TLANDO XR (LPCN 1111), LPCN 1148 and LPCN 1107 development programs. TLANDO, a novel oral

prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal

men and received a Complete Response Letter from the U.S. Food and Drug Administration on November 8, 2019. LPCN 1144, a differentiated

oral product of bioidentical testosterone, is currently undergoing Phase 2 clinical testing in biopsy confirmed NASH patients

and recently completed a proof-of-concept clinical study demonstrating the potential utility the in treatment of NASH. TLANDO

XR (LPCN 1111), a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral

testosterone product with potential for once-daily dosing and has completed Phase 2 testing. LPCN 1148 is a unique oral testosterone

product targeted to treat NASH cirrhosis. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate

indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. An End of Phase

2 meeting with the FDA has been completed. For more information, please visit www.lipocine.com.

Forward-Looking Statements

This release contains "forward-looking statements"

that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements

that are not historical facts regarding Lipocine's product candidates and related clinical trials, the timing of completion

of clinical trials, the potential uses and benefits of our product candidates, our product development efforts and future discussions

and actions with the FDA related to TLANDO. Investors are cautioned that all such forward-looking statements involve risks and

uncertainties, including, without limitation, the risks that the FDA will not approve any of our products, risks related to our

products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new

regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals,

the results and timing of clinical trials, patient acceptance of Lipocine's products, the manufacturing and commercialization of

Lipocine's products, risk related to on-going litigation and other risks detailed in Lipocine's filings with the SEC, including,

without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov.

Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as

For further information:

Executive Vice President & Chief Financial Officer

Phone: (801) 994-7383

Phone: (617) 535-7743